The Cooper Companies, Inc. (NASDAQ:COO) CFO Sells $2,625,049.20 in Stock

The Cooper Companies, Inc. (NASDAQ:COO) CFO Brian G. Andrews sold 24,788 shares of the firm’s stock in a transaction dated Thursday, September 5th. The shares were sold at an average price of $105.90, for a total value of $2,625,049.20. Following the completion of the transaction, the chief financial officer now owns 6,614 shares in the company, valued at approximately $700,422.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Cooper Companies Stock Performance

COO stock opened at $106.59 on Friday. The Cooper Companies, Inc. has a 1-year low of $75.93 and a 1-year high of $107.82. The company has a current ratio of 1.99, a quick ratio of 1.14 and a debt-to-equity ratio of 0.33. The firm has a market cap of $21.22 billion, a PE ratio of 62.70, a P/E/G ratio of 2.56 and a beta of 0.98. The business’s 50-day moving average price is $93.30 and its two-hundred day moving average price is $94.64.

Cooper Companies (NASDAQ:COO) last released its quarterly earnings data on Wednesday, August 28th. The medical device company reported $0.96 earnings per share for the quarter, beating the consensus estimate of $0.91 by $0.05. Cooper Companies had a return on equity of 9.08% and a net margin of 9.45%. The business had revenue of $1 billion for the quarter, compared to analysts’ expectations of $997.30 million. During the same quarter in the previous year, the business posted $0.84 EPS. Cooper Companies’s revenue for the quarter was up 7.8% on a year-over-year basis. As a group, research analysts forecast that The Cooper Companies, Inc. will post 3.66 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on COO. Needham & Company LLC reaffirmed a “hold” rating on shares of Cooper Companies in a research note on Thursday, August 29th. Stifel Nicolaus restated a “buy” rating and issued a $115.00 price objective (up from $110.00) on shares of Cooper Companies in a report on Thursday, August 29th. Piper Sandler lifted their target price on shares of Cooper Companies from $115.00 to $120.00 and gave the stock an “overweight” rating in a report on Thursday, August 29th. Robert W. Baird upped their target price on shares of Cooper Companies from $118.00 to $125.00 and gave the company an “outperform” rating in a research report on Thursday, August 29th. Finally, Jefferies Financial Group upgraded Cooper Companies from a “hold” rating to a “buy” rating and raised their price target for the stock from $107.00 to $115.00 in a research report on Tuesday, July 16th. Four research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat, Cooper Companies presently has a consensus rating of “Moderate Buy” and a consensus target price of $113.61.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Benjamin F. Edwards & Company Inc. lifted its position in Cooper Companies by 248.6% in the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 244 shares of the medical device company’s stock valued at $25,000 after acquiring an additional 174 shares in the last quarter. Innealta Capital LLC bought a new stake in shares of Cooper Companies in the second quarter valued at about $25,000. Covestor Ltd boosted its position in shares of Cooper Companies by 305.9% during the first quarter. Covestor Ltd now owns 276 shares of the medical device company’s stock worth $28,000 after buying an additional 208 shares during the period. Crewe Advisors LLC grew its holdings in shares of Cooper Companies by 286.4% during the second quarter. Crewe Advisors LLC now owns 340 shares of the medical device company’s stock worth $30,000 after buying an additional 252 shares in the last quarter. Finally, Global Retirement Partners LLC raised its position in Cooper Companies by 358.6% in the 1st quarter. Global Retirement Partners LLC now owns 321 shares of the medical device company’s stock valued at $33,000 after buying an additional 251 shares during the last quarter. Institutional investors and hedge funds own 24.39% of the company’s stock.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.